Tactoset is a calcium phosphate-based injectable bone substitute designed for hardware augmentation, according to a July 27 news release. It was launched in 2019 and received FDA 510(k) clearance for the augmentation of hardware in 2021.
“Winning this award from the American Orthopedic Society for Sports Medicine truly validates the benefits Tactoset brings to the sports medicine surgeon and the patients that they treat,” Steve Ek, Anika’s vice president of research and development, said in the release. “Prior to this innovation, surgeons experiencing poor bone quality had to adjust their technique and/or insert larger hardware to try and provide a secure repair for their patients. Tactoset is a quick, simple and highly effective solution that allows surgeons to augment the repair without requiring anchor repositioning or larger sizes.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
